Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study

BACKGROUND: M5717 is the first plasmodium translation elongation factor 2 inhibitor to reach clinical development as an antimalarial. We aimed to characterise the safety, pharmacokinetics, and antimalarial activity of M5717 in healthy volunteers. METHODS: This first-in-human study was a two-part, si...

Descripción completa

Detalles Bibliográficos
Autores principales: McCarthy, James S, Yalkinoglu, Özkan, Odedra, Anand, Webster, Rebecca, Oeuvray, Claude, Tappert, Aliona, Bezuidenhout, Deon, Giddins, Marla J, Dhingra, Satish K, Fidock, David A, Marquart, Louise, Webb, Lachlan, Yin, Xiaoyan, Khandelwal, Akash, Bagchus, Wilhelmina M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612936/
https://www.ncbi.nlm.nih.gov/pubmed/34715032
http://dx.doi.org/10.1016/S1473-3099(21)00252-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612936/
https://www.ncbi.nlm.nih.gov/pubmed/34715032
http://dx.doi.org/10.1016/S1473-3099(21)00252-8

Ejemplares similares